Multiple myeloma idiotype (MM-Id)

The multiple myeloma idiotype refers to the unique collection of antigenic determinants (epitopes) located within the variable regions of the monoclonal immunoglobulin, or M-protein, produced by malignant plasma cells. Because each patient's myeloma clone originates from a single B-cell, the resulting immunoglobulin possesses a unique amino acid sequence in its heavy and light chain variable domains, making the idiotype a highly specific tumor-specific antigen (TSA). In therapeutic applications, this idiotype is utilized as a target for personalized immunotherapy, typically through the development of idiotype vaccines where the patient's own M-protein is conjugated to an adjuvant or pulsed onto dendritic cells. These treatments aim to overcome the host's immune tolerance and stimulate a targeted attack against the cancerous plasma cells while sparing healthy B-cells. Although idiotype-based therapies have shown promise in clinical trials for inducing specific immune responses, their widespread adoption is hindered by the requirement for custom, patient-specific manufacturing and the immunosuppressive environment characteristic of advanced multiple myeloma.

Other names

M-protein idiotypeParaprotein idiotypeMyeloma-specific idiotypeImmunoglobulin variable region determinantsB-cell idiotype

Active immunotherapy designed to induce idiotype-specific cytotoxic T-lymphocytes (CTLs) and humoral immune responses against the monoclonal plasma cell population.